Statin Therapy: Review of Safety and Potential Side Effects
- PMID: 27899849
- PMCID: PMC5126440
- DOI: 10.6515/acs20160611a
Statin Therapy: Review of Safety and Potential Side Effects
Abstract
Background: Hydroxymethyl glutaryl coenzyme A reductase inhibitors, commonly called statins, are some of the most commonly prescribed medications worldwide. Evidence suggests that statin therapy has significant mortality and morbidity benefit for both primary and secondary prevention from cardiovascular disease. Nonetheless, concern has been expressed regarding the adverse effects of long term statin use. The purpose of this article was to review the current medical literature regarding the safety of statins.
Methods: Major trials and review articles on the safety of statins were identified in a search of the MEDLINE database from 1980 to 2016, which was limited to English articles.
Results: Myalgia is the most common side effect of statin use, with documented rates from 1-10%. Rhabdomyolysis is the most serious adverse effect from statin use, though it occurs quite rarely (less than 0.1%). The most common risk factors for statin-related myopathy include hypothyroidism, polypharmacy and alcohol abuse. Derangement in liver function tests is common, affecting up to 1% of patients; however, the clinical significance of this is unknown. Some statin drugs are potentially diabetogenic and the risk appears to increase in those patients on higher doses. Pitavastatin has not been associated with increased risk of diabetes. Statins have not been proven to increase the risk of malignancy, dementia, mood disorders or acute interstitial nephritis. However, statins do have multiple drug interactions, primarily those which interact with the cytochrome p450 enzyme group.
Conclusions: Overall, statin drugs appear to be safe for use in the vast majority of patients. However, patients with multiple medical co-morbidities are at increased risk of adverse effects from long-term statin use.
Keywords: Dyslipidemia; Hypercholesterolemia; Statin.
Similar articles
-
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.Am J Cardiovasc Drugs. 2010;10(1):11-28. doi: 10.2165/13168600-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20104931 Review.
-
Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.Curr Vasc Pharmacol. 2012 Mar;10(2):257-67. doi: 10.2174/157016112799305021. Curr Vasc Pharmacol. 2012. PMID: 22022768 Review.
-
[Adverse effects of statins].Therapie. 2003 Jan-Feb;58(1):77-83. doi: 10.2515/therapie:2003011. Therapie. 2003. PMID: 12822204 Review. French.
-
Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?Drug Saf. 2002;25(9):649-63. doi: 10.2165/00002018-200225090-00004. Drug Saf. 2002. PMID: 12137559 Review.
-
Safety considerations for statins.Curr Opin Lipidol. 2002 Dec;13(6):637-44. doi: 10.1097/00041433-200212000-00007. Curr Opin Lipidol. 2002. PMID: 12441888 Review.
Cited by
-
Navigating the Statin Landscape: A Comprehensive Review of Stroke Prevention Strategies.Cureus. 2024 Feb 4;16(2):e53555. doi: 10.7759/cureus.53555. eCollection 2024 Feb. Cureus. 2024. PMID: 38445155 Free PMC article. Review.
-
Updates on Non-Statin LDL-Lowering Therapy.Curr Cardiol Rep. 2024 Mar 4. doi: 10.1007/s11886-024-02028-3. Online ahead of print. Curr Cardiol Rep. 2024. PMID: 38436784 Review.
-
Calcium Blood Level Elevation After Atorvastatin Initiation in a Patient With Hyperparathyroidism.Cureus. 2024 Jan 31;16(1):e53306. doi: 10.7759/cureus.53306. eCollection 2024 Jan. Cureus. 2024. PMID: 38435925 Free PMC article.
-
Homeopathic preparation of Allium sativum abrogates OxLDL mediated atherogenic events in macrophages: An invitro and in silico approach.J Ayurveda Integr Med. 2024 Jan 13;15(1):100850. doi: 10.1016/j.jaim.2023.100850. Online ahead of print. J Ayurveda Integr Med. 2024. PMID: 38219436 Free PMC article.
-
The Impact of an 8-Week Supplementation with Fermented and Non-Fermented Aronia Berry Pulp on Cardiovascular Risk Factors in Individuals with Type 2 Diabetes.Nutrients. 2023 Dec 13;15(24):5094. doi: 10.3390/nu15245094. Nutrients. 2023. PMID: 38140354 Free PMC article. Clinical Trial.
References
-
- Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL)-The PATROL trial. Circ J. 2011;75(6):1493–1505. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources